Pathological Complete Response Likely Not a Reliable Survival Surrogate in Early Breast Cancer

A new meta-analysis suggests that pathological complete response should not be used as a surrogate endpoint in randomized trials of neoadjuvant therapies for early breast cancer.
Reuters Health Information

source https://www.medscape.com/viewarticle/966719?src=rss

Comments

Popular posts from this blog

DC’s Harllee Harper Is Using Public Health Tools to Prevent Gun Violence. Will It Work?